Pulmonary Sarcoidosis Market 2026-2036: Mapping 8MM Growth Opportunities, Epidemiology Trends, and Emerging Therapies | Thelansis

Source Summary

A newly published report breaks down the shifting pulmonary sarcoidosis treatment landscape, from first-in-class biologics in late-stage trials to the real commercial gaps still waiting to be solved. Pulmonary sarcoidosis has long been treated as a "steroids-first, figure-it-out-later" disease. That's changing